Loading
Nuo Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SHEEDY CHARLES E, was filed 01 Aug 2025.
Nuo Therapeutics, Inc.: what insiders have been doing
Nuo Therapeutics, Inc., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (22 October 2025 to 22 October 2026), 8 filings came from 3 insiders.
Only sales appear on the open market, 1 sale in all totalling €259k, filed by 1 insider. Biggest ticket of the year: €259k, sold by Jorden David Emerson and made public on 3 December 2025.
Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For context, the typical company on the same exchange (median of 277 companies) published 8 filings over the same period, against 8 filings here. Looking back to 2016, when coverage begins, insiders filed 16 purchases and 8 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 3.3 m USD and net income at -2.5 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
65
Thresholds
n/a
Buy Volume
€4M
16 ops. · all time
Sell Volume
€426,021
8 ops. · all time
Who traded when
BuySaleCharles E. Sheedy1 buy
David Emerson Jorden1 sale
Since the insiders bought
- -37.5%Entry US$1.60 · Close at T+365 US$1.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,514 of 26,250 companies
34.9
score / 100
Value27
Quality43
FCF yld-1.8%
Earn yld-4.0%
EV/EBITDA·
ROE·
Gross mgn67%
Net mgn-76%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.30
Analyst consensus
Income statement
RevenueUS$3.3M
Gross profitUS$2.2M67% margin
EBITDA-US$2.4M-71% margin
Net income-US$2.5M-38.7% margin
Valuation
Beta-881.25
Balance sheet & cash
Market capUS$63M
Total debtUS$597.3k
Free Cash Flow-US$1.1M
Profitability & ownership
ROA-54.3%
% insiders57.9%
% institutions0.0%
Last declaration on 28 August 2026
Declarations65 total
789 shares@ US$1.070.0013% mcap0.2% of flowCommon StockSEC:0001437749-26-029236:0
7,984 shares@ US$1.0890.014% mcap1.9% of flowCommon StockSEC:0001437749-26-029236:1
25,381 shares@ US$1.976.3% of flowCommon StockSEC:0001437749-26-000431:1
125,000 shares@ US$0.4010.7% of flowCommon StockSEC:0001437749-26-000431:0
68,750 shares@ US$0.4035.7% of flowCommon StockSEC:0001437749-25-038506:0
9,091 shares@ US$2.2018.0% of flowCommon StockSEC:0001437749-25-037591:1
50,000 shares@ US$0.4035.9% of flowCommon StockSEC:0001437749-25-037614:0
200,000 shares@ US$1.5064.8% of flowCommon StockSEC:0001437749-25-036821:0
27,659 shares@ US$1.7439.1% of flowCommon StockSEC:0001437749-25-024508:1
92,710 shares@ US$0.404.8% of flowCommon StockSEC:0001437749-25-024497:1
21,313 shares@ US$1.744.8% of flowCommon StockSEC:0001437749-25-024497:2
20,115 shares@ US$1.7432.0% of flowCommon StockSEC:0001437749-25-024499:1
87,500 shares@ US$0.4064.1% of flowCommon StockSEC:0001437749-25-024499:0
120,313 shares@ US$0.4064.3% of flowCommon StockSEC:0001437749-25-024508:0
100,000 shares@ US$0.408.8% of flowCommon StockSEC:0001437749-25-024497:0
183,853 shares@ US$0.4042.0% of flowCommon StockSEC:0001437749-25-024493:0
3,946 shares@ US$1.500.7% of flowCommon StockSEC:0001437749-25-024429:0
133,333 shares@ US$1.5013.7% of flowCommon StockSEC:0001437749-25-024427:0
Canonical exit: 28 Oct 2025 (T+90)
62,500 shares@ US$0.401.9% of flowCommon StockSEC:0001437749-24-035771:1
33,334 shares@ US$0.501.3% of flowCommon StockSEC:0001437749-24-035771:2
121,875 shares@ US$0.406.6% of flowCommon StockSEC:0001437749-24-035771:0
125,000 shares@ US$0.756.6% of flowCommon StockSEC:0001437749-24-029634:0
Canonical exit: 17 Dec 2024 (T+90)
100,000 shares@ US$0.755.4% of flowCommon StockSEC:0001437749-24-017815:0
Canonical exit: 18 Aug 2024 (T+90)
135,000 shares@ US$0.7513.4% of flowCommon StockSEC:0001437749-24-017813:0
15,000 shares@ US$0.756.8% of flowCommon StockSEC:0001437749-24-017814:0
25 of 65 declarations
About Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. is a biotechnology company focused on developing treatments for chronic diseases. It aims to provide innovative solutions to enhance patient health.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
